N Katsumata

Summary

Affiliation: National Cancer Center
Country: Japan

Publications

  1. pmc Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chem
    Noriyuki Katsumata
    Department of Medical Oncology, National Cancer Center, Tokyo, Japan
    Jpn J Clin Oncol 38:777-85. 2008
  2. doi Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial
    Noriyuki Katsumata
    Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
    Lancet 374:1331-8. 2009
  3. doi Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802)
    N Katsumata
    Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
    Ann Oncol 20:1210-5. 2009
  4. pmc Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer
    N Katsumata
    Department of Medical Oncology, National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
    Ann Oncol 22:1353-7. 2011
  5. pmc Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study
    N Katsumata
    Department of Medical Oncology, National Cancer Center Hospital, 104 0045 Tokyo, Japan
    Br J Cancer 93:999-1004. 2005
  6. pmc Docetaxel: an alternative taxane in ovarian cancer
    N Katsumata
    Department of Medical Oncology, National Cancer Centre Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Br J Cancer 89:S9-S15. 2003
  7. doi Prediction of progressive disease using tumor markers in metastatic breast cancer patients without target lesions in first-line chemotherapy
    K Hashimoto
    Breast and Medical Oncology Division, National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
    Ann Oncol 21:2195-200. 2010
  8. pmc Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy
    M Tanioka
    Breast and Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Br J Cancer 103:297-302. 2010
  9. doi FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer
    K Tamura
    Department of Breast and Medical Oncology, National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
    Ann Oncol 22:1302-7. 2011
  10. ncbi Accuracy of contrast-enhanced computed tomography in the prediction of residual breast cancer after neoadjuvant chemotherapy
    S Akashi-Tanaka
    Division of Surgical Oncology, National Cancer Center Hospital, Tokyo, Japan
    Int J Cancer 96:66-73. 2001

Detail Information

Publications27

  1. pmc Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chem
    Noriyuki Katsumata
    Department of Medical Oncology, National Cancer Center, Tokyo, Japan
    Jpn J Clin Oncol 38:777-85. 2008
    ..This study was conducted to evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) in Japanese patients with Müllerian carcinoma having a therapeutic history of platinum-based chemotherapy...
  2. doi Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial
    Noriyuki Katsumata
    Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
    Lancet 374:1331-8. 2009
    ..Attempts to improve patient survival by including other drugs have yielded disappointing results. We compared a conventional regimen of paclitaxel and carboplatin with a dose-dense weekly regimen in women with advanced ovarian cancer...
  3. doi Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802)
    N Katsumata
    Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
    Ann Oncol 20:1210-5. 2009
    ..This randomized, multicenter, phase III trial compared doxorubicin plus cyclophosphamide (AC), single-agent docetaxel (D), and an alternating regimen of AC and docetaxel (AC-D) as first-line chemotherapy in metastatic breast cancer (MBC)...
  4. pmc Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer
    N Katsumata
    Department of Medical Oncology, National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
    Ann Oncol 22:1353-7. 2011
    ..S-1 is an oral fluoropyrimidine. This phase II study was designed to evaluate the efficacy and safety of S-1 in patients with advanced or recurrent uterine cervical cancer...
  5. pmc Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study
    N Katsumata
    Department of Medical Oncology, National Cancer Center Hospital, 104 0045 Tokyo, Japan
    Br J Cancer 93:999-1004. 2005
    ....
  6. pmc Docetaxel: an alternative taxane in ovarian cancer
    N Katsumata
    Department of Medical Oncology, National Cancer Centre Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Br J Cancer 89:S9-S15. 2003
    ....
  7. doi Prediction of progressive disease using tumor markers in metastatic breast cancer patients without target lesions in first-line chemotherapy
    K Hashimoto
    Breast and Medical Oncology Division, National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
    Ann Oncol 21:2195-200. 2010
    ..The aim of this study was to develop a prediction model of progressive disease (PD) in breast cancer patients without measurable disease in first-line chemotherapy...
  8. pmc Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy
    M Tanioka
    Breast and Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Br J Cancer 103:297-302. 2010
    ..This study was designed to identify factors predictive of recurrence in patients with pCR...
  9. doi FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer
    K Tamura
    Department of Breast and Medical Oncology, National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
    Ann Oncol 22:1302-7. 2011
    ..This prospective phase II trial aimed to evaluate whether these polymorphisms are associated with clinical efficacies in patients who received trastuzumab...
  10. ncbi Accuracy of contrast-enhanced computed tomography in the prediction of residual breast cancer after neoadjuvant chemotherapy
    S Akashi-Tanaka
    Division of Surgical Oncology, National Cancer Center Hospital, Tokyo, Japan
    Int J Cancer 96:66-73. 2001
    ..In conclusion, CE-CT is the most accurate noninvasive technique for identifying the extent of the residual carcinoma after neoadjuvant chemotherapy if cases of IBC and ILC are excluded...
  11. doi Efficacy of pleurodesis for malignant pleural effusions in breast cancer patients
    T Hirata
    Dept of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo 104 0045, Japan
    Eur Respir J 38:1425-30. 2011
    ..24. Our results suggest that the efficacy of P-ST may be superior to that of ST alone with respect to local control of pleural effusions in breast cancer patients...
  12. doi Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041)
    H Nomura
    Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo, Japan
    Ann Oncol 22:636-42. 2011
    ..The purpose of this study is to assess the efficacy and safety of treatment with taxane plus platinum in combination therapies for advanced or recurrent endometrial carcinoma...
  13. ncbi A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: a Japanese cooperative study
    N Katsumata
    National Cancer Center Hospital, Tokyo, Japan
    Ann Oncol 11:1531-6. 2000
    ..This phase II study was conducted to evaluate the efficacy and toxicity of docetaxel in Japanese patients with advanced ovarian cancer...
  14. pmc Irinotecan plus carboplatin for patients with carcinoma of unknown primary site
    K Yonemori
    Breast and Medical Oncology Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Br J Cancer 100:50-5. 2009
    ..Therefore, the regimen may be one of the potentially available chemotherapeutic options for community standard of care in patients with a good performance status...
  15. doi Clinical characteristics and outcomes of women with stage IV endometrial cancer
    M Tanioka
    Division of Breast and Medical Oncology, National Cancer Center Hospital Tokyo, Tsukiji 5 1 1, Chuo Ku, Tokyo, Japan
    Med Oncol 27:1371-7. 2010
    ..In women with stage IV EC, histologic features and extent of disease are more important determinants of outcomes than any kind of treatment. The indication for surgery should be carefully considered in this subset of patients...
  16. doi Compliance with Good Clinical Practice in oncology registration trials in Japan
    K Yonemori
    Department of Breast and Medical Oncology, National Cancer Center Hospital, Chuo Ku, Tokyo 103 0045, Japan
    Ann Oncol 22:1451-6. 2011
    ....
  17. pmc A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer
    M Ando
    Department of Medicine, National Cancer Center Hospital, Tokyo, Japan
    Br J Cancer 77:1937-43. 1998
    ..The recommended doses of docetaxel and 5-day continuous infusion of 5-FU for a phase II trial are 50 mg m(-2) and 500 mg m(-2) per day every 3 or 4 weeks...
  18. ncbi Efficacy of docetaxel 60 mg/m2 in patients with metastatic breast cancer according to the status of anthracycline resistance
    M Ando
    Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
    J Clin Oncol 19:336-42. 2001
    ..The status of anthracycline resistance is important for the prediction of response to second-line treatment with docetaxel...
  19. ncbi Two special types of breast cancer presenting as progressive disease after neoadjuvant chemotherapy with docetaxel plus doxorubicin
    T Takahashi
    Breasr Surgery Division, National Cancer Hospital, Tokyo, Japan
    Breast Cancer 8:234-7. 2001
    ..There were 4 cases of IBC and one case of SCC of the breast who received neoadjuvant chemotherapy in this series. Our observations suggest that this regimen might not be effective for these types of breast cancer...
  20. pmc Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102)
    N Katsumata
    Department of Medical Oncology, Nippon Medical School Musashikosugi Hospital, Kawasaki, Japan
    Br J Cancer 108:1957-63. 2013
    ..A phase III trial was conducted to determine whether neoadjuvant chemotherapy (NACT) before radical surgery (RS) improves overall survival...
  21. doi Dose-dense therapy is of benefit in primary treatment of ovarian cancer? In favor
    N Katsumata
    Department of Medical Oncology, Nippon Medical School, Musashikosugi Hospital, 1 396 Kosugi machi, Nakahara ku, Kawasaki City, Kanagawa Prefecture, Japan
    Ann Oncol 22:viii29-viii32. 2011
    ..0015], as was the overall survival at 3 years (72.1% versus 65.1%; HR 0.75; 95% CI: 0.57-0.98; P=0.03). Dose-dense weekly paclitaxel plus carboplatin represents a new treatment option in women with advanced epithelial ovarian cancer...
  22. ncbi Phase II study of KRN8602, 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin hydrochloride, MX2 x HCl in patients with metastatic breast cancer
    N Katsumata
    Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
    Cancer Chemother Pharmacol 43:441-4. 1999
    ..In order to clinically confirm these promising preclinical observations, we performed a phase II trial of KRN8602 in patients with anthracycline-resistant metastatic breast cancer...
  23. pmc Prognostic significance of positive peritoneal cytology in endometrial carcinoma confined to the uterus
    T Kasamatsu
    Division of Gynecology, National Cancer Center Hospital, Tokyo, Japan
    Br J Cancer 88:245-50. 2003
    ....
  24. ncbi Mental adjustment to first recurrence and correlated factors in patients with breast cancer
    Y Okano
    Psycho Oncology Division, National Cancer Center Research Institute East, Chiba, Japan
    Breast Cancer Res Treat 67:255-62. 2001
    ....
  25. pmc Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer
    T Hirata
    Department of Breast and Medical Oncology, National Cancer Center Hospital, Chuo Ku, Tokyo 104 0045, Japan
    Br J Cancer 101:1529-36. 2009
    ..To evaluate the impact of change in the hormone receptor (HR) status (HR status conversion) on the long-term outcomes of breast cancer patients treated with neoadjuvant chemotherapy (NAC)...
  26. ncbi Three novel PHEX gene mutations in Japanese patients with X-linked hypophosphatemic rickets
    K Sato
    Department of Pediatrics, Hokkaido University School of Medicine, N15, W7, Kita ku, Sapporo, Japan 060 8638
    Pediatr Res 48:536-40. 2000
    ..These results suggest that: 1) PHEX gene mutations are responsible for XLH in Japanese patients, and 2) PHEX gene mutations are heterogeneous in the Japanese population similarly to other ethnic populations...
  27. ncbi Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer: Japan Clinical Oncology Group study, JCOG 9208
    Yutaka Tokuda
    Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259 1193, Japan
    Cancer Sci 99:145-51. 2008
    ..78). Although the prespecified values of the two arms were not so accurate as to allow detection of the observed difference, no advantage of HDC was observed in terms of RFS or overall survival...